Search Results

Nicox SA announced the signature of an agreement granting Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing, exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS ® (celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients.

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

Check out five New York companies hiring biopharma professionals like you, including 2025 Best Places to Work winners.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updated clinical results from the ongoing investigator-sponsored Phase 2 trial of darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C, as neoadjuvant/adjuvant treatment in uveal melanoma and clinical update for Phase 2 company-sponsored neoadjuvant UM study.

Many biopharma professionals view smaller companies as having the best flexibility and remote work options, but that doesn’t mean their larger counterparts are failing in that area. Several professionals, including Apogee Therapeutics and Insmed executives, share their insights.

Esteve Pharmaceuticals (ESTEVE), an international specialty pharmaceutical company devoted to the development and commercialization of innovative products, today announced an agreement with Kowa Pharmaceuticals America, Inc.